Clinical trials recruiting in Delhi, India

Phase breakdown

Conditions recruiting in Delhi, India

Recruiting trials in Delhi, India

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
  NCT05953584 · Phase: Phase 2 · Ages: 12 Years to 16 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female)
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
  NCT07282613 · Phase: Phase 3 · Ages: 10 Years to 18 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  NCT07361497 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  NCT07221357 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
  NCT07606066 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female)
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
  NCT06932263 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
  NCT06429761 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06350097 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT07222566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The PURI-HF (Air Purifiers on Heart Failure) Trial
  NCT05230784 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer
  NCT02992574 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: Female
• Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
  NCT06676384 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Delhi, India?

35 recruiting trials have at least one study site in Delhi, India.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.